CellaVision AB (publ)
CellaVision AB (publ) (CLVSF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
clvsf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CellaVision AB (publ) (CLVSF) measures how much investors pay for each dollar of the company's trailing earnings. CLVSF's current PE ratio of 22.70x is calculated by dividing its stock price of $13.49 by its TTM earnings per share of $5.62. −45.8% discount vs 5Y avg 41.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%30.8x
MedianQ3 · 75%106.9x
Max
At 22.70x, CLVSF's current P/E is within its average historical range over the past 19 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CellaVision AB (publ)You CLVSF | $322M | 22.70x | -53.4% | $5.62 |
 Avon Technologies Plc AVNBF | $627M | 78.12x | +60.3% | $0.36 |
 Beijing Tong Ren Tang Chinese Medicine Company Limited BJTRF | $536M | 10.64x | -78.2% | $0.47 |
 Boiron S.A. BOIRF | $554M | 42.15x | -13.5% | $0.65 |
 PolyNovo Limited CALZF | $415M | 64.01x | +31.4% | $0.02 |
 4DMedical Limited FDMDF | $1.6B | N/A | — | -$0.14 |
 GenSight Biologics S.A. GSGTF | $31M | N/A | — | -$0.08 |
Industry Average 4 peers with valid PE | — | 48.73x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 24.18x | $6.42 | -50.2% | |
2024-12-31 FY2024 | 48.58x | $5.90 | +57.6% | |
2023-12-31 FY2023 | 30.82x | $5.46 | -34.6% | |
2022-12-31 FY2022 | 47.11x | $4.96 | -20.0% | |
2021-12-31 FY2021 | 58.91x | $5.25 | -12.2% | |
2020-12-31 FY2020 | 67.12x | $3.75 | +1.2% | |
2019-12-31 FY2019 | 66.35x | $4.16 | +18.6% | |
2018-12-31 FY2018 | 55.97x | $3.72 | +13.5% | |
2017-12-31 FY2017 | 49.32x | $2.92 | +106.1% | |
2016-12-31 FY2016 | 23.92x | $2.51 | -5.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CellaVision AB (publ) (CLVSF) measures how much investors pay for each dollar of the company's trailing earnings. CLVSF's current PE ratio of 22.70x is calculated by dividing its stock price of $13.49 by its TTM earnings per share of $5.62.
Frequently asked questions
CLVSF pe ratio · 6 questionsCLVSF's current PE ratio is 22.70x as of 2026-06-09, based on a stock price of $13.49 and TTM EPS of $5.62. Data sourced from Financial Modeling Prep via CLVSF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CellaVision AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09